Bisphosphonates: Their evolving role in the management of prostate cancer-related bone disease

Current Opinion in Urology

Volumn 12, Issue 5, 2002, Pages 413-418

  Dawson, Nancy A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Bisphosphonates; Bone metastases; Prostate cancer

Indexed keywords

ALENDRONIC ACID; ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DEOXYPYRIDINOLINE; ESTRAMUSTINE; ETIDRONIC ACID; IBANDRONIC ACID; INTERLEUKIN 1; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MATRIX METALLOPROTEINASE; OLPADRONIC ACID; OSTEOCALCIN; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; RISEDRONIC ACID; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID;

BONE ATROPHY; BONE DENSITY; BONE DISEASE; BONE METASTASIS; BONE PAIN; DRUG MECHANISM; FRACTURE; HUMAN; MALE; MORBIDITY; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

BONE DISEASES; DIPHOSPHONATES; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0036739706     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200209000-00008     Document Type: Review

References (57)

1. Jacobs SC. Spread of prostate cancer to bone. Urology 1983; 21:337-344.
2. Berruti A, Dogliotti L, Bitossi R, et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000; 164:1248-1253.
3. Carlin BI, Andriole G. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88(suppl):2989-2994.
4. Coleman RE. Should bisphosphonates be the treatment of choice for metastatic bone disease? Semin Oncol 2001; 28:35-41.
5. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 2000; 18:1378-1391.
6. Body J-J. Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 2001; 28(suppl 2):49-53.
7. Roodman CD. Biology of osteoclast activation in cancer. J Clin Oncol 2001; 19:3562-3571.
8. Berruti A, Dogliotti L, Tucci M, et al. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol 2001; 166:2023-2031.
9. Saharabudhe C, Maurer C, Hassett R, et al. Effect of androgen-ablation on bone resorption in men with prostate cancer [abstract 734]. Proc Am Soc Clin Oncol 2001; 20:184a.
10. Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev 2001; 3:187-192.
11. Garnero P, Buchs N, Zekri J, et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000; 4:858-864.
12. Pelger RCM, Soerdjbalie-Maikoe V, Hamdy NAT. Strategies for the management of prostate cancer-related bone pain. Drug Aging 2001; 18:899-911.
13. Virtanen SS, Vaananen HK, Harkonen PL, Lakkakorpi PT. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002; 62:2708-2714.
14. Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 2002; 167:1952-1956.
15. Gholz RC, Conde F, Rutledge DN. Osteoporosis in men treated with androgen suppression therapy for prostate cancer. Clin J Oncol Nurs 2002; 6:88-93.
16. Smith MR, Shasha D, Mansour R, et al. Zometa increases bone mineral density in men undergoing androgen deprivation therapy for prostate cancer. Skeletal Complications of Malignancies, Third North American Symposium, Meeting Proceedings, Bethesda, Maryland, USA, 2002; Abstract C8: 25-27.
17. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low mineral density. N Engl J Med 2002; 346:653-661.
18. Diamond TH, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade, a double blind, randomized, placebo-controlled cross-over study. Cancer 2001; 92:1444-1450.
19. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343:604-610.
20. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345:948-955.
21. Adami S, Salvangno G, Guarrera G, et al. Dichloromethylenediphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol 1985; 134:1152-1154.
22. Adami S, Mian M. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Cancer Res 1989; 116:67-72.
23. Adami S. Bisphosphonates in prostate carcinoma. Cancer 1997; 80(suppl):1674-1679.
24. Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 2001; 165:136-140.
25. Strang P, Nilsson S, Brandstedt S, et al. The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res 1997; 17:4717-4721.
26. Kylmala T, Taubr T, Tammela TL, et al. Concomitant i.v. and oral clodronate in the relief of bone pain - a double-blind, placebo controlled study in patients with prostate cancer. Br J Cancer 1997; 76:939-942.
27. Coleman RE, Purohit OP, Vinholes JJ, et al. High-dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer 1997; 80(suppl):1652-1660.
28. Lipton A, Glover D, Harvey H, et al. Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann Oncol 1994; 5(suppl 7):S31-S35.
29. Lipton A, Small E, Saad F, et al. The new bisphosphonate, zometa (zoledronic acid) decreases skeletal complications in both lytic and blastic lesions: a comparison to pamidronate. Cancer Invest 2002; 20(suppl 1):44-46.
30. Johnson IS. Use of bisphosphonates for the treatment of metastatic bone pain: a survey of palliative physicians in the UK. Palliat Med 2001; 2:141-147.
31. Pelger RCM, Hamdy NAT, Zwiderman AH, et al. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 1998; 22:403-408.
32. Soerdjbalie-Maikoe V, Pelger RCM, Lycklama a Nijeholt AAB, et al. Palliation of bone pain by the bisphosphonate olpadronate in hormone-escaped prostate adenocarcinoma metastatic to the skeleton [Abstract]. J Urol 2000; 163:261.
33. Heidenreich A, von Knobloch R, Elert A, Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 2002; 5:1-5.
34. Berenson JR, Liechtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal event in-patients with advanced multiple myeloma. N Engl J Med 1996; 334:488-493.
35. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998; 16:593-602.
36. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335:1785-1791.
37. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized placebo-controlled trial. J Clin Oncol 1999; 17:846-854.
38. Rosen LS, Gordon D, Kaminiski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7:377-387.
39. Fred S, Gleason D, Murray R, et al. Zoledronic acid significantly reduces fractures in patients with hormone-refractory prostate cancer metastatic to bone [abstract 703]. J Urol 2002; 167(suppl 4):175.
40. US Food and Drug Administration. Zometa® (zoledronic acid for injection): for intravenous infusion. http://www.fda.gov/eder/foi/label/2002/21386lbl.pdf. [Accessed 17 June 2002]
41. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61:2602-2608.
42. Senarative SG, Oades GM, Pickering LM, et al. The bisphosphonate zoledronic acid induces apoptosis by impairing Ras membrane localization and inducing cytochrome c release in breast and prostate cancer cells [abstract 4311]. Proc Am Assoc Cancer Res 2002; 43:871.
43. Senarative SG, Pirianov G, Mansi JL, et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82:1459-1468.
44. Clezardin P, Gligorov J, Delmas P. Mechanisms of action of bisphosphonates on tumor cells and prospects for use in treatment of malignant osteolysis. Joint Bone Spine 2000; 67:22-29.
45. Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997; 57:3890-3894.
46. Bossier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60:2949-2954.
47. Teronen O, Heikkila P, Konttinen YT, et al. MMP inhibition and down regulation by bisphosphonates. Ann NY Acad Sci 1999; 878:453-465.
48. Futakuchi M, Hikosaka A, Ogawa K, et al. A prostate cancer bone invasion model showing osteolytic and osteoblastic reactions and effects of bisphosphonates on invasion [abstract 5258]. Proc Am Assoc Cancer Res 2002; 43:1061.
49. Fischer C, Neudert M, Krempien F, et al. Ibandronic acid prevents the development and induces remission of bone metastases in a nude rat model of human breast cancer [abstract 332]. Proc Am Soc Clin Oncol 2002; 20:84a.
50. Coleman RE, Seaman JJ. The role of zoledronic acid in cancer clinical studies in the treatment and prevention of bone metastases. Semin Oncol 2001; 28(suppl 6):11-16.
51. Diel IJ. Bisphosphonates in the prevention of bone metastases: current evidence. Semin Oncol 2001; 28(suppl 6):75-80.
52. Kanis JA, Powles TJ, Paterson AHG, et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996; 19:663-667.
53. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339:357-363.
54. Diel IJ, Solomayer EF, Bastert G. Bisphosphonates in the prevention of metastases in breast cancer results of the extended follow-up study [Abstract]. Proc Am Soc Clin Oncol 2000; 19:314.
55. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer: 5-year results of a randomized controlled trial. J Clin Oncol 2001; 19:10-17.
56. Dearnaley DP, Sydes MR, on behalf of the MRC PRO5 collaboration. Preliminary evidence that oral clodronate delays symptomatic progression of bone metastases from prostate cancer: first results of the MRC Pro5 trial [abstract 693]. Proc Am Soc Clin Oncol 2001; 20:174a.
57. Jones J. Bisphosphonates may be useful in treatment of bone metastases. J Natl Cancer Inst 2001; 93:1052-1053.